Myeloproliferative Neoplasms News

ASH awarded $150,000 each to eight investigators through the society’s bridge grant program, designed to sustain promising hematologic research proposals that are not funded through NIH.

The FDA granted priority review to ruxolitinib for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids, according to the agent’s manufacturer.

A novel online calculator that combines genetic and clinical data appeared to better predict individual disease outcomes than current classification systems among patients with myeloproliferative neoplasms, according to study results published in The New England Journal of Medicine.

Treatment with ruxolitinib plus azacytidine yielded encouraging spleen response rates and improvement in bone marrow fibrosis among patients with myelofibrosis, according an open-label, single-arm phase 2 study.

A new tool that incorporates genetic and clinical variables may represent a convenient and effective method of predicting outcomes among patients with myelodysplastic syndrome, according to study results published in Mayo Clinic Proceedings.

The FDA awarded more than $18 million in grants over the next 4 years to fund clinical trials of medical products intended to treat patients with rare diseases.

Patients who died within 1 year of undergoing inpatient allogeneic hematopoietic stem cell transplantation often received medically intense end-of-life care that may not have matched their wishes, according to a retrospective population-based analysis.

Individuals with cancer appeared 10 times less likely than the general population to die as a result of opioid use, according to retrospective study results presented at ASCO Quality Care Symposium.

Patients with myelodysplastic syndrome who had persistent mutations detected in bone marrow samples after allogeneic hematopoietic stem cell transplantation appeared at increased risk for disease progression, according to an exploratory study published in The New England Journal of Medicine.

The Leukemia & Lymphoma Society has deemed September Blood Cancer Awareness Month.